In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Vertex's total revenues for Q4 2024 were $178.5 million, marking a 15.2% increase year-over-year. How much did Vertex invest in research and development for 2025? Vertex plans to invest ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Self-cleaving ribozymes are RNA molecules that catalyze the cleavage of their own phosphodiester backbones. These ribozymes are found in all domains of life and are also a tool for biotechnical and ...

A self-cleaving element for use in bioseparations has been derived from a naturally occurring, 43 kDa protein splicing element (intein) through a combination of protein engineering and random ...